The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma
Open accessAbstract
Five biologicals have been approved for severe eosinophilic asthma, a well‐recognized phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared to standard of care for severe eosinophilic asthma. PubMed, Embase and Cochrane Library were searched to identify RCTs and health economic evaluations, published in English. Critical and important asthma‐related outcomes were evaluated for each of the biologicals. The risk of bias and the certainty of the evidence were assessed using GRADE. 19 RCTs (three RCTs for benralizumab, three RCTs for dupilumab, three RCTs for mepolizumab, five RCTs for omalizumab and five RCTs for reslizumab), including subjects 12 to 75 years old (except for omalizumab including also subjects 6‐11 years old), ranging from 12 to 56 weeks were evaluated. All biologicals reduce exacerbation rates with high certainty of evidence: benralizumab incidence rate ratio (IRR) 0.53 (95% CI 0.39 to 0.72), dupilumab (IRR) 0.43 (95% CI 0.32 to 0.59), mepolizumab IRR 0.49 (95% CI 0.38 to 0.66), omalizumab (IRR) 0.56 (95% CI 0.40 to 0.77) and reslizumab (IRR) 0.46 (95% CI 0.37 to 0.58). Benralizumab, dupilumab and mepolizumab reduce the daily dose of oral corticosteroids (OCS) with high certainty of evidence. All evaluated biologicals probably improve asthma control, QoL and FEV 1, without reaching the minimal important difference (moderate certainty). Benralizumab, mepolizumab and reslizumab slightly increase drug‐related adverse events (AE) and drug‐related serious AE (low to very low certainty of evidence). The incremental cost‐effectiveness ratio per quality‐adjusted life year value is above the willingness to pay threshold for all biologicals (moderate certainty). Potential savings are driven by decrease in hospitalizations, emergency and primary care visits. There is high certainty that all approved biologicals reduce the rate of severe asthma exacerbations and for benralizumab, dupilumab and mepolizumab for reducing OCS. There is moderate certainty for improving asthma control, QoL, FEV 1. More data on long‐term safety are needed together with more efficacy data in the paediatric population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Self-citationInternational ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Dweik, R. A., Boggs, P. B., Erzurum, S. C., Irvin, C. G., Leigh, M. W., Lundberg, J. O., Olin, A.-C., Plummer, A. L., & Taylor, D. R. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.9120-11st · Cited by 2,539
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Castro, M., Corren, J., Pavord, I. D., Maspero, J., Wenzel, S., Rabe, K. F., Busse, W. W., Ford, L., Sher, L., FitzGerald, J. M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804092 · Cited by 1,986
Self-citationPapi, A., Brightling, C., Pedersen, S. E., & Reddel, H. K. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33311-1 · Cited by 1,759
Self-citationAsthma exacerbations and sputum eosinophil counts: a randomised controlled trial
Green, R. H., Brightling, C. E., McKenna, S., Hargadon, B., Parker, D., Bradding, P., Wardlaw, A. J., & Pavord, I. D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11679-5 · Cited by 1,755
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Bel, E. H., Wenzel, S. E., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S. W., Ortega, H. G., & Pavord, I. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403291 · Cited by 1,661
Bleecker, E. R., FitzGerald, J. M., Chanez, P., Papi, A., Weinstein, S. F., Barker, P., Sproule, S., Gilmartin, G., Aurivillius, M., Werkström, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31324-1 · Cited by 1,406
Self-citationFitzGerald, J. M., Bleecker, E. R., Nair, P., Korn, S., Ohta, K., Lommatzsch, M., Ferguson, G. T., Busse, W. W., Barker, P., Sproule, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31322-8 · Cited by 1,397
Self-citationGRADE guidelines: 9. Rating up the quality of evidence
Guyatt, G. H., Oxman, A. D., Sultan, S., Glasziou, P., Akl, E. A., Alonso-Coello, P., Atkins, D., Kunz, R., Brozek, J., Montori, V., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.06.004 · Cited by 1,336
Self-citationEfficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Rabe, K. F., Nair, P., Brusselle, G., Maspero, J. F., Castro, M., Sher, L., Zhu, H., Hamilton, J. D., Swanson, B. N., Khan, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804093 · Cited by 1,184
Self-citationCastro, M., Zangrilli, J., Wechsler, M. E., Bateman, E. D., Brusselle, G. G., Bardin, P., Murphy, K., Maspero, J. F., O'Brien, C., & Korn, S. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00042-9 · Cited by 1,182
Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
Nair, P., Wenzel, S., Rabe, K. F., Bourdin, A., Lugogo, N. L., Kuna, P., Barker, P., Sproule, S., Ponnarambil, S., & Goldman, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703501 · Cited by 1,044
Self-citationJuniper, E. F., Svensson, K., Mörk, A.-C., & Ståhl, E. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.10.008 · Cited by 929
Exploring the Effects of Omalizumab in Allergic Asthma: An Analysis of Biomarkers in the EXTRA Study
Hanania, N. A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D. F., Lal, P., Arron, J. R., Harris, J. M., & Busse, W. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1414oc · Cited by 901
Self-citationWenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 889
Self-citationEvers, S., Goossens, M., de Vet, H., van Tulder, M., & Ament, A. (2005) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462305050324 · Cited by 856
Reslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-controlled Study
Castro, M., Mathur, S., Hargreave, F., Boulet, L.-P., Xie, F., Young, J., Wilkins, H. J., Henkel, T., & Nair, P. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201103-0396oc · Cited by 716
Self-citationChupp, G. L., Bradford, E. S., Albers, F. C., Bratton, D. J., Wang-Jairaj, J., Nelsen, L. M., Trevor, J. L., Magnan, A., & ten Brinke, A. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30125-x · Cited by 599
Interpreting thresholds for a clinically significant change in health status in asthma and COPD
Jones, P. W. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00063702 · Cited by 585
Wagener, A. H., de Nijs, S. B., Lutter, R., Sousa, A. R., Weersink, E. J. M., Bel, E. H., & Sterk, P. J. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-205634 · Cited by 429
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
Bjermer, L., Lemiere, C., Maspero, J., Weiss, S., Zangrilli, J., & Germinaro, M. (2016) · Chest · doi:10.1016/j.chest.2016.03.032 · Cited by 426
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma
Corren, J., Weinstein, S., Janka, L., Zangrilli, J., & Garin, M. (2016) · Chest · doi:10.1016/j.chest.2016.03.018 · Cited by 388
Self-citationAgache, I., & Akdis, C. A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124611 · Cited by 313
Self-citationWhat are minimal important changes for asthma measures in a clinical trial?
Santanello, N. C., Zhang, J., Seidenberg, B., Reiss, T. F., & Barber, B. L. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14a06.x · Cited by 275
Hastie, A. T., Moore, W. C., Li, H., Rector, B. M., Ortega, V. E., Pascual, R. M., Peters, S. P., Meyers, D. A., & Bleecker, E. R. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.03.044 · Cited by 260
Methods for including information from multi-arm trials in pairwise meta-analysis
Rücker, G., Cates, C. J., & Schwarzer, G. (2017) · Research Synthesis Methods · doi:10.1002/jrsm.1259 · Cited by 251
Willsie, S. K. (2012) · Yearbook of Pulmonary Disease · doi:10.1016/j.ypdi.2012.02.004 · Cited by 243
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Sismondo, S., Busuioc, O. A., & Bero, L. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033 · Cited by 166
Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma
Casale, T. B., Chipps, B. E., Rosén, K., Trzaskoma, B., Haselkorn, T., Omachi, T. A., Greenberg, S., & Hanania, N. A. (2018) · Allergy · doi:10.1111/all.13302 · Cited by 158
Self-citationDiagnosis and management of eosinophilic asthma: a US perspective
Doherty, T. A., & Walford, H. (2014) · Journal of Asthma and Allergy · doi:10.2147/jaa.s39119 · Cited by 138
Characterization of asthma endotypes: implications for therapy
Stokes, J. R., & Casale, T. B. (2016) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2016.05.016 · Cited by 116
Self-citationPetsky, H., Li, A., & Chang, A. B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005603.pub3 · Cited by 114
Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
Yancey, S. W., Ortega, H. G., Keene, O. N., Mayer, B., Gunsoy, N. B., Brightling, C. E., Bleecker, E. R., Haldar, P., & Pavord, I. D. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.08.008 · Cited by 97
Goldman, M. A., Hirsch, I., Zangrilli, J., Newbold, P., & Xu, X. P. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1347091 · Cited by 96
McQueen, R. B., Sheehan, D. N., Whittington, M. D., van Boven, J. F. M., & Campbell, J. D. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0658-x · Cited by 94
Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis
Whittington, M. D., McQueen, R. B., Ollendorf, D. A., Tice, J. A., Chapman, R. H., Pearson, S. D., & Campbell, J. D. (2016) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2016.10.028 · Cited by 84
Severe asthma phenotypes and endotypes
Agache, I. O. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101301 · Cited by 84
Self-citationSorkness, C. A., Wildfire, J. J., Calatroni, A., Mitchell, H., Busse, W. W., O’Connor, G. T., Pongracic, J. A., Ross, K. R., Gill, M. A., Kattan, M., et al. (2013) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2013.01.011 · Cited by 79
dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies
Palomares, Ó., Sánchez‐Ramón, S., Davila, I. J., Prieto, L. M., de Llano, L. P., Lleonart, M., Domingo, C., & Nieto, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061328 · Cited by 73
Agache, I. O., Strasser, D. S., Klenk, A., Agache, C., Farine, H., Ciobanu, C., Groenen, P. M. A., & Akdiş, C. A. (2016) · Allergy · doi:10.1111/all.12906 · Cited by 70
Self-citationGuidelines for completing the EURONHEED transferability information checklists
Nixon, J., Rice, S. J. C., Drummond, M., Boulenger, S., Ulmann, P., & de Pouvourville, G. (2008) · The European Journal of Health Economics · doi:10.1007/s10198-008-0115-4 · Cited by 61
Pelaia, C., Busceti, M. T., Solinas, S., Terracciano, R., & Pelaia, G. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.09.006 · Cited by 60
Eosinophils Target Therapy for Severe Asthma: Critical Points
Brussino, L., Heffler, E. M., Bucca, C. B., Nicola, S., & Rolla, G. (2018) · BioMed Research International · doi:10.1155/2018/7582057 · Cited by 51
Bime, C., Wei, C. Y., Holbrook, J. T., Sockrider, M. M., Revicki, D. A., & Wise, R. A. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.058 · Cited by 49
Pelaia, C., Calabrese, C., Barbuto, S., Busceti, M. T., Preianò, M., Gallelli, L., Savino, R., Vatrella, A., & Pelaia, G. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.11.002 · Cited by 40
Li, J., Wang, F., Lin, C., Du, J., Xiao, B., Du, C., & Sun, J. (2016) · Journal of Asthma · doi:10.1080/02770903.2016.1212371 · Cited by 36
de Llano, L. A. P., Martínez‐Moragón, E., Plaza, V., Trisán, A., Sánchez, C. A., Callejas, F. J., Vera, E., Campos, J. G. S., Martínez‐Rivera, C., Navarrete, B. A., et al. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.03.006 · Cited by 36
Tian, B., Zhang, G., Lou, J., Zhou, H., & Cui, W. (2017) · Journal of Asthma · doi:10.1080/02770903.2017.1379534 · Cited by 35
Lam, J., Hay, J. W., Salcedo, J. D., & Kenyon, N. J. (2018) · Journal of Asthma · doi:10.1080/02770903.2018.1500584 · Cited by 22
Colombo, G. L., Matteo, S. D., Martinotti, C., Oselin, M., Valentino, M. C., Bruno, G. M., Pitotti, C., & Menzella, F. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619841350 · Cited by 17
Mepolizumab in the treatment of severe eosinophilic asthma
Strauss, R. A., & Jawhari, N. (2018) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2018.04.016 · Cited by 13
Corren, J., Kavati, A., Ortiz, B. D., Vegesna, A., Colby, J. A., Ruiz, K., & Panettieri, R. A. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1395734 · Cited by 10
Self-citation
Cited by
Type 2 immunity in the skin and lungs
Akdis, C. A., Arkwright, P. D., Brüggen, M.-C., Busse, W., Gadina, M., Guttman‐Yassky, E., Kabashima, K., Mitamura, Y., Vian, L., Wu, J., et al. (2020) · Allergy · doi:10.1111/all.14318 · Cited by 560
Self-citationInternational consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Self-citationEAACI Biologicals Guidelines—Recommendations for severe asthma
Agache, I., Akdis, C. A., Akdis, M., Canonica, G. W., Casale, T., Chivato, T., Corren, J., Chu, D. K., Del Giacco, S., Eiwegger, T., et al. (2021) · Allergy · doi:10.1111/all.14425 · Cited by 275
Self-citationBiologics and airway remodeling in severe asthma
Varricchi, G., Ferri, S., Pepys, J., Poto, R., Spadaro, G., Nappi, E., Paoletti, G., Virchow, J. C., Heffler, E., & Canonica, W. G. (2022) · Allergy · doi:10.1111/all.15473 · Cited by 254
Dysregulation of the epithelial barrier by environmental and other exogenous factors
Mitamura, Y., Ogulur, I., Pat, Y., Rinaldi, A. O., Ardicli, O., Cevhertas, L., Brüggen, M., Traidl‐Hoffmann, C., Akdis, M., & Akdis, C. A. (2021) · Contact Dermatitis · doi:10.1111/cod.13959 · Cited by 85
Metadata
- Authors
- Agache, I., Beltran, J., Akdis, C., Akdis, M., Canelo‐Aybar, C., Canonica, G. W., Casale, T., Chivato, T., Corren, J., Del Giacco, S., Eiwegger, T., Firinu, D., Gern, J. E., Hamelmann, E., Hanania, N., Mäkelä, M., Hernández‐Martín, I., Nair, P., O'Mahony, L., Papadopoulos, N. G., Papi, A., Park, H., Pérez de Llano, L., Posso, M., Rocha, C., Quirce, S., Sastre, J., Shamji, M., Song, Y., Steiner, C., Schwarze, J., Alonso‐Coello, P., Palomares, O., & Jutel, M.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2020-02-24
- Volume
- 75
- Issue
- 5
- Pages
- 1023-1042
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W3004838051
- Cited by
- 408
- References
- 55
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.